Artiva Biotherapeutics
Update in progressARTV (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Artiva Biotherapeutics is a clinical-stage biotech focused on developing natural killer (NK) cell therapies for autoimmune diseases and cancers. Its lead program, AlloNK, is an off-the-shelf NK cell therapy for conditions such as rheumatoid arthritis, systemic lupus erythematosus and related vasculitis, pemphigus vulgaris, and B-cell non-Hodgkin lymphoma. Additional programs include AB-201, a HER2-targeted CAR-NK for solid tumors, and AB-205, a CD5 CAR-NK for hematologic cancers. Founded in 2019 and based in San Diego, California.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Fred Aslan M.D.
- Founded2019
- Employees115
- Websitewww.artivabio.com
Identifiers
- ISINUS04317A1079
- FIGIBBG00VPZJ0F9